Moody's: $8.7 billion acquisition of AveXis strengthens Novartis's pipeline in gene therapy, but reduces financial flexibility
On 9 April 2018, Novartis AG (Aa3 negative) announced that it had entered into an agreement to acquire AveXis Inc for $8.7 billion. The transaction, which has been approved by the board of directors of both companies, is expected to close by the middle of 2018 and will be funded by the $13 billi...
Moody's Investors Service is a leading provider of credit ratings, research, and risk analysis. Moody's commitment and expertise contributes to transparent and integrated financial markets, protecting the integrity of credit. Our ratings and analysis track debt covering more than:
- 130 countries
11,000 corporate issuers
21,000 public finance issuers
76,000 structured finance obligations
Credit ratings and research help investors analyze the credit risks associated with fixed-income securities. Such independent credit ratings and research also contribute to efficiencies in fixed-income markets and other obligations, such as insurance policies and derivative transactions, by providing credible and independent assessments of credit risk.
Moody’s default studies validate our predictive ratings. Our published research and investor briefings draw thousands of attendees each year and keep investors current with the rationale underlying our credit opinions.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.